Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Advanced Non-Small Cell Lung Cancer
NCT00459342Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2007
- Primary completion
- Apr 2012
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dasatinib in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Primary endpoints: Number of Participants With Objective Response (Complete Response (CR) or Partial Response (PR)) at 12 weeks and Progression-free Survival at 2 months. Started Mar 2007; status: completed.
02
Drugs
dasatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00459342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00459342.